IP Verse

Sglt 2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy - EP3362055

PATENT ANALYSIS

Patent Details

Grant Date
Jan 18, 2023
Company
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Oppositions

GENERICS (U.K.) LIMITED

SANDOZ AG

More patents of Boehringer Ingelheim International Gmbh

EP2313087

EP3110449

EP3802922

Want to monitor this patent?

Feel free to send us a message here and we will get back to you